Skip to main content
main-content

01.10.2014 | Original | Ausgabe 10/2014 Open Access

Intensive Care Medicine 10/2014

Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period

Zeitschrift:
Intensive Care Medicine > Ausgabe 10/2014
Autoren:
Arnaldo L. Colombo, Thais Guimarães, Teresa Sukienik, Alessandro C. Pasqualotto, Ricardo Andreotti, Flavio Queiroz-Telles, Simone A. Nouér, Marcio Nucci
Wichtige Hinweise
Take-home message: We observed that the mortality rate of candidemia in ICU patients decreased in recent years and that receipt of an echinocandin as primary therapy was associated with lower 30-day mortality.
An erratum to this article can be found at http://​dx.​doi.​org/​10.​1007/​s00134-014-3527-x.

Introduction

Despite the best efforts of the medical community, the morbidity and mortality associated with candidemia remains elevated, with crude mortality rates of ≥40 % [ 13]. In addition, population-based studies conducted in the USA and Europe suggest that the incidence of candidemia has increased during the last decade [ 46]. Patients admitted to intensive care units (ICUs) are at high risk of developing candidemia, with recent multicenter studies reporting that 30–40 % of candidemic patients were in ICUs at the time of the diagnosis. Delays in initiating antifungal therapy may increase mortality rates in patients with candidemia [ 7, 8]. Consequently, serious attempts have been directed to validating predictive guidelines based on risk factors and/or the presence of fungal biomarkers in order to assist clinicians in their decision to provide early antifungal therapy to patients at high risk [ 912].
In Latin America, overall mortality rates of patients with candidemia are usually higher than those observed in the Northern Hemisphere [ 1315]. However, it should be noted that data on the epidemiology and prognostic factors associated with candidemia in patients admitted to ICUs in Latin America are scarce. Therefore, the main objective of this study was to evaluate historical trends in the epidemiology and clinical management of patients admitted to ICUs in tertiary care hospitals in Brazil, as well as to identify the prognostic factors of candidemia.

Patients and methods

Patient selection and data collection

This is a retrospective analysis of a collection of candidemia cases created by merging the databases of five prospective laboratory-based surveillance cohorts conducted in 22 tertiary care medical centers in Brazil between March 2003 and February 2012. Only tertiary care hospitals providing medical care in most medical specialties participated in these five studies, and they can be categorized as public hospitals ( n = 13), which provide medical assistance to low-income patients, and private hospitals ( n = 9), which are for-profit medical institutions that provide care mostly to patients covered by private insurance plans. These hospitals are representative of public and private reference medical centers located in 12 large cities in Brazil. In the first two cohorts, only patients from public hospitals were enrolled, while in the latter three cohort studies, the patients were from a mixture of public and private hospitals.
An investigator at each medical center was assigned the specific task of contacting the microbiology laboratory of the hospital on a weekly basis in order to collect clinical and epidemiological data of all incident cases of candidemia. This investigator was trained to record such data on a standard case report form using a dictionary of terms that included all definitions of underlying conditions and medical exposures collected during the study. The case report form, dictionary of terms and strategy for data collection were the same in all five surveillance studies. Patients were followed up to 30 days after the incident candidemia or death. A case of candidemia was defined as the incident isolation of Candida spp. from a blood culture. The date of the incident candidemia was defined as the date of the collection of the blood culture that became positive for Candida species. Candidemia occurring >30 days after the incident isolation was defined as a new case. Fever was defined as an axillary temperature of ≥37.8 °C and neutropenia as an absolute neutrophil count of <500/mm 3. Cardiac and lung diseases were considered if the patient presented any cardiac or lung condition requiring active treatment. Such conditions included (but were not restricted to) congestive heart failure, coronary arterial disease, hypertension and cardiac arrhythmias (cardiac diseases), as well as chronic obstructive pulmonary disease, asthma, emphysema, bronchiectasis or chronic pneumonia or interstitial disease of any etiology (lung disease). Renal failure was defined as any documented serum creatinine value of >1.5 g/dL.
With the exception of invasive medical procedures and antibiotic use, we considered all these manifestations documented up to 30 days before the date of the incident candidemia as conditions associated with candidemia. Data on central venous catheters, dialysis and antibiotic use were captured up to 15 days before the onset of candidemia. Data on surgery requiring general anesthesia was captured up to 3 months before candidemia. All medical records were reviewed and monitored by a central data collection system for the analysis of completeness and consistency. In cases of uncompleted or inconsistent clinical forms, queries were generated and sent back to the investigators for corrections or completion.

Yeast identification

All Candida bloodstream isolates were sent to a central laboratory (Special Mycology Laboratory, Escola Paulista de Medicina, UNIFESP) for further species identification based on the micromorphologic characteristics of the colonies and biochemical tests (ID 32C system; BioMérieux, Marcy l’Etoile, France).

Data analysis

For this analysis we excluded patients aged <18 years. We compared candidemia occurring in ICU patients versus non-ICU patients in terms of baseline characteristics, clinical manifestations, species distribution, treatment and outcome. In addition, we arbitrarily defined two 5-year periods (2003–2007, period 1; 2008–2012, period 2) and compared the epidemiological characteristics of ICU patients admitted in these two periods. Additional analyses included comparison of the epidemiology of candidemia in ICU patients from public versus private institutions. Finally, prognostic factors for ICU patients with candidemia were identified by comparing patients who died versus those who survived for 30 days after the candidemia episode.
Categorical variables were analyzed using chi-square or Fisher’s exact tests, as appropriate, and continuous variables were compared using the Wilcoxon test. A p value of <0.05 was considered to be statistically significant. Variables significant at p < 0.1 by univariate analysis were included in a multivariate model (backward and forward). Statistical analyses were performed using SPSS version 15.0 (SPSS, Inc., Chicago, IL).

Results

A total of 1,392 episodes of candidemia were collected for analysis. The median age of the patient cohort was 62 (range 18–97) years, and 718 were males. C. albicans was the leading etiologic agent of candidemia (42 %), followed by C. tropicalis (20 %), C. parapsilosis (19 %) and C. glabrata (9 %). The 30-day crude mortality rate was 62.4 %.
In 647 episodes (46.5 %) the patient was in an ICU at the time candidemia was diagnosed. Comparison between these patients and those who were not in an ICU is shown in Table  1 where it can be seen that ICU patients were older (median of 66 vs. 58 years, p < 0.001) and more likely to present comorbidities such as renal failure and neurologic, cardiac or lung disease. Likewise, ICU patients were more likely to have been exposed to surgery, dialysis, mechanical ventilation, central venous catheterization and antibiotics. However, non-ICU patients with candidemia were more likely to have cancer (especially hematologic malignancies), organ transplantation and auto-immune diseases. Non-ICU patients were also more likely to have neutropenia and to have received anticancer chemotherapy and immunosuppressive drugs. The 30-day crude mortality rate was 70.3 % in ICU patients and 52.6 % in non-ICU patients ( p < 0.001). In terms of species distribution, the only significant difference was a lower proportion of C. parapsilosis among ICU patients (17.2 vs. 21.7 %, p = 0.03). Of note, both the proportion of C. glabrata candidemia and prior exposure to azoles were similar among ICU and non-ICU patients.
Table 1
Characteristics of patients admitted to an intensive care unit (ICU) versus those of patients not in an ICU at the time of candidemia diagnosis
Variable
In the ICU ( N = 647)
Outside the ICU ( N = 745)
p
Gender ( N, male:female)
328:319
390:355
0.54
Age (years)
66 (18–97)
58 (18–97)
<0.001
Time (days) from admission to candidemia diagnosis
20 (0–188)
20 (0–159)
0.83
Cancer
174 (26.9)
283 (38.0)
<0.001
  Hematologic
29 (4.5)
95 (12.8)
<0.001
  Solid tumor
145 (22.4)
188 (25.2)
0.22
Diabetes
154 (24.4)
170 (22.8)
0.48
Renal failure
262 (40.5)
217 (29.1)
<0.001
Chronic renal failure
81 (12.5)
113 (15.2)
0.15
Dialysis
183 (28.3)
118 (15.8)
<0.001
Liver disease
74 (11.4)
91 (12.2)
0.65
Auto-immune disease
28 (4.3)
52 (7.0)
0.03
Neurologic disease
160 (24.7)
141 (18.9)
0.009
Transplant
3 (0.5)
27 (3.6)
<0.001
Cardiac disease
227 (35.1)
163 (21.9)
<0.001
Lung disease
185 (28.6)
120 (16.1)
<0.001
Surgery
336 (51.9)
328 (44.0)
0.003
Abdominal surgery
194 (30.0)
189 (25.4)
0.05
Mechanical ventilation
480 (74.2)
120 (16.1)
<0.001
Total parenteral nutrition
140 (21.6)
157 (21.1)
0.80
Central venous catheter
605 (93.5)
591 (79.3)
<0.001
Neutropenia
16 (2.5)
51 (6.8)
<0.001
Prior drug/treatment exposure
  Antibiotics
622 (96.1)
653 (87.7)
<0.001
  Corticosteroids
338 (52.2)
223 (29.9)
<0.001
  Other immunosuppressive drugs
38 (5.9)
67 (9.0)
0.03
  Chemotherapy
22 (3.4)
76 (10.2)
<0.001
  Fluconazole prior to candidemia
102 (15.8)
108 (14.5)
0.51
Candida spp.
   C. albicans
285 (44.0)
300 (40.3)
0.15
   C. parapsilosis
111 (17.2)
162 (21.7)
0.03
   C. tropicalis
141 (21.8)
140 (18.8)
0.16
   C. glabrata
64 (9.9)
68 (9.1)
0.63
   C. krusei
16 (2.5)
21 (2.8)
0.69
   C. guilliermondii
12 (1.9)
22 (3.0)
0.19
Treatment received
482 (74.5)
577 (77.4)
0.20
  Fluconazole
295/482 (61.2)
395/577 (68.5)
0.01
  Deoxycholate AMB
106/482 (22.0)
106/577 (18.4)
0.14
  Lipid AMB
21/482 (4.4)
8/577 (1.4)
0.003
  Echinocandins
52/482 (10.8)
33/577 (5.7)
0.002
30-day crude mortality
450/640 (70.3) a
389/740 (52.6) b
<0.001
AMB, Amphotericin B
Data are presented as a number with the percentage given in parenthesis, or as the median with the range given in parenthesis, unless specified otherwise
aStatus on day 30 was not known in 7 patients
bStatus on day 30 was not known in 5 patients
The proportion of patients who developed candidemia while in the ICU increased from 44 % in period 1 to 50.9 % in period 2 ( p = 0.01). Table  2 shows the comparisons of episodes in the two periods. As expected, the proportion of patients in private hospitals was higher in period 2, as was the proportion of patients with liver or neurologic diseases. Prior exposure to fluconazole (22.3 vs. 11.6 %, p < 0.001) and candidemia due to C. glabrata (13.1 vs. 7.8 %, p = 0.03) were also more frequent in period 2. Of note, the increase in the proportion of C. glabrata over the entire study period was mostly driven by a change in the proportion of public institutions [5.1 (period 1) vs. 10.5 % (period 2), p = 0.07] compared to private centers [11.1 (period 1) vs. 15.1 % (period 2), p = 0.29].
Table 2
Characteristics of ICU patients with candidemia in the two study periods, 2003–2007 (period 1) and 2008–2012 (period 2)
Variable
Period 1 ( N = 396)
Period 2 ( N = 251)
p
Gender ( N, male:female)
206:190
122:129
0.40
Age (years)
67 (18–97)
63 (19–97)
0.67
Time (days) from admission to candidemia diagnosis
21 (0–142)
16 (0–188)
0.01
Private hospital
340 (37.8)
242 (49.3)
<0.001
APACHE II score, median (range) a
27 (0–46)
22 (3–42)
0.08
Cancer
102 (25.8)
72 (28.7)
0.41
  Hematologic
14 (3.5)
15 (6.0)
0.14
  Solid tumor
88 (22.2)
57 (22.7)
0.88
Diabetes
96 (24.2)
62 (24.7)
0.89
Renal failure
162 (40.9)
100 (39.8)
0.79
Chronic renal failure
57 (14.4)
24 (9.6)
0.07
Dialysis
112 (28.3)
71 (28.3)
1.00
Liver disease
32 (8.1)
42 (16.7)
0.001
Auto-immune disease
18 (4.5)
10 (4.0)
0.73
Neurologic disease
83 (21.0)
77 (30.7)
0.005
Transplant
2 (0.5)
1 (0.4)
1.00
Cardiac disease
142 (35.9)
85 (33.9)
0.60
Lung disease
106 (26.8)
79 (31.5)
0.20
Surgery
205 (51.8)
131 (52.2)
0.92
Abdominal surgery
129 (32.6)
66 (25.9)
0.07
Mechanical ventilation
296 (74.7)
184 (73.3)
0.68
Total parenteral nutrition
83 (21.0)
57 (22.7)
0.60
Central venous catheter
364 (91.9)
241 (96.0)
0.04
Neutropenia
9 (2.3)
7 (2.8)
0.68
Prior drug/treatment exposure
  Antibiotics
377 (95.2)
245 (97.6)
0.12
  Corticosteroids
202 (51.0)
136 (54.2)
0.43
  Other immunosuppressive drugs
23 (5.8)
15 (6.0)
0.93
  Chemotherapy
7 (1.8)
15 (6.0)
0.004
  Fluconazole prior to candidemia
46 (11.6)
56 (22.3)
<0.001
Candida spp.
   C. albicans
177 (44.7)
108 (43.0)
0.68
   C. parapsilosis
72 (18.2)
39 (15.5)
0.38
   C. tropicalis
90 (22.7)
51 (20.3)
0.47
   C. glabrata
31 (7.8)
33 (13.1)
0.03
   C. krusei
5 (1.3)
11 (4.4)
0.01
   C. guilliermondii
9 (2.3)
3 (1.2)
0.38
Treatment received
288 (72.7)
194 (77.3)
0.19
  Fluconazole
174/288 (60.4)
121/194 (62.4)
0.67
  Deoxycholate AMB b
80/288 (27.8)
26/194 (13.4)
<0.001
  Lipid AMB b
9/288 (3.1)
12/194 (6.2)
0.11
  Echinocandin
17/288 (5.9)
35/194 (18.0)
<0.001
30-day crude mortality
298/390 (76.4) c
152/250 (60.8) d
<0.001
Data are presented as a number with the percentage given in parenthesis, or as the median with the range given in parenthesis, unless specified otherwise
aAPACHE, Acute physiologic and chronic health evaluation (Data available for 261 patients only)
bAMB, amphotericin B
cStatus on day 30 was not known in 6 patients
dStatus on day 30 was not known in 1 patient
Antifungal treatment was given to 72.7 % of patients in period 1 and 77.3 % in period 2 ( p = 0.19). During the study period the antifungal drugs prescribed for the primary treatment of candidemia changed, with a decrease in the use of deoxycholate amphotericin B (27.8 vs. 13.4 %, p < 0.001) and an increase in the use of echinocandins (5.9 vs. 18.0 %, p < 0.001). The use of lipid formulations of amphotericin B also increased from period 1 to period 2 (3.1 vs. 6.2 %, p = 0.11), but the difference was not statistically significant. Of interest, the 30-day crude mortality rate decreased from 76.4 % in period 1 to 60.8 % in period 2 ( p < 0.001).
The main characteristics of candidemic patients according to admission to ICUs of public or private hospitals are shown in Table  3. Patients in public hospitals were significantly younger, and a higher proportion had autoimmune and lung diseases; in private hospitals, a higher number of patients had neutropenia and received cancer chemotherapy. In terms of species distribution, C. albicans was more frequently isolated in public institutions (48.6 vs. 39.6 %, p = 0.02), whereas C. glabrata (12.9 vs. 6.9 %, p = 0.01) and C. krusei (3.7 vs. 1.2 %, p = 0.05) were more prone to be isolated in private medical centers. In terms of antifungal therapy, echinocandins (2.9 vs. 18.5 %, p < 0.001) and lipid formulations of amphotericin B (1.3 vs. 7.4 %, p = 0.001) were more likely to be used for the treatment of candidemia in private institutions, whereas deoxycholate amphotericin B was more frequently used in the public institutions (31.8 vs. 12.3 %, p < 0.001). The 30-day crude mortality rate was 75.3 % in the public hospitals and 65.3 % in private institutions ( p = 0.006).
Table 3
Characteristics of patients with candidemia according to admission to ICUs of public and private hospitals
Variable
Public ( N = 321)
Private ( N = 326)
p
Gender ( N, male:female)
169:152
159:167
0.32
Age (years)
60 (18–97)
64 (18–97)
<0.001
Time (days) from admission to candidemia
20 (0–188)
19 (0–159)
0.62
Cancer
79 (24.6)
95 (29.1)
0.19
  Hematologic
10 (3.1)
19 (5.8)
0.09
  Solid tumor
69 (21.5)
76 (23.3)
0.58
Diabetes
69 (21.5)
89 (27.3)
0.09
Renal failure
126 (39.3)
136 (41.7)
0.52
Chronic renal failure
45 (14.0)
36 (11.0)
0.25
Dialysis
88 (27.4)
95 (29.1)
0.63
Liver disease
34 (10.6)
40 (12.3)
0.50
Auto-immune disease
20 (6.2)
8 (2.5)
0.02
Neurologic disease
75 (23.4)
85 (25.1)
0.42
Transplant
1 (0.3)
2 (0.6)
1.00
Cardiac disease
113 (35.2)
114 (35.0)
0.95
Lung disease
106 (33.0)
79 (24.2)
0.01
Surgery
164 (51.1)
172 (52.8)
0.67
Abdominal surgery
96 (29.9)
98 (30.1)
0.97
Mechanical ventilation
247 (76.9)
233 (71.5)
0.11
Total parenteral nutrition
68 (21.2)
72 (22.1)
0.78
Central venous catheter
297 (92.5)
308 (94.5)
0.31
Neutropenia
3 (0.9)
13 (4.0)
0.01
Prior drug/treatment exposure
  Antibiotics
310 (96.6)
312 (95.7)
0.57
  Corticosteroids
173 (53.9)
165 (50.6)
0.40
  Immunosuppressive drugs
18 (5.6)
20 (6.1)
0.77
  Chemotherapy
4 (1.2)
18 (5.5)
0.003
  Fluconazole prior to candidemia
43 (13.4)
59 (18.1)
0.10
Candida spp.
   C. albicans
156 (48.6)
129 (39.6)
0.02
   C. parapsilosis
61 (19.0)
50 (15.3)
0.22
   C. tropicalis
64 (19.9)
77 (23.6)
0.26
   C. glabrata
22 (6.9)
42 (12.9)
0.01
   C. krusei
4 (1.2)
12 (3.7)
0.05
   C. guilliermondii
7 (2.2)
5 (1.5)
0.54
Treatment received
239 (74.5)
243 (74.5)
0.98
  Fluconazole
147/239 (61.5)
148/243 (60.9)
0.89
  Deoxycholate AMB
76/239 (31.8)
30/243 (12.3)
<0.001
  Lipid AMB
3/239 (1.3)
18/243 (7.4)
0.001
  Echinocandin
7/239 (2.9)
45/243 (18.5)
<0.001
30-day crude mortality
241/320 (75.3) a
209/320 (65.3) b
0.006
Data are presented as a number with the percentage given in parenthesis, or as the median with the range given in parenthesis, unless specified otherwise
aStatus on day 30 was not known in 1 patient
bStatus on day 30 was not known in 6 patients
As shown in Table  4, the following variables were associated with higher 30-day mortality by univariate analysis: older age, period 1, public hospital, higher acute physiologic and chronic health evaluation (APACHE) II score, cancer, lung disease, renal failure, dialysis, mechanical ventilation, receipt of corticosteroids, no treatment for candidemia and treatment with deoxycholate amphotericin B. Infection due to C. parapsilosis and treatment with an echinocandin were associated with lower mortality.
Table 4
Factors associated with 30-day mortality among 640 ICU patients a with candidemia by univariate analysis
Variable
Alive ( N = 190)
Dead ( N = 450)
p value
Gender ( N, male:female)
94:96
233:217
0.59
Age (years)
60 (19–97)
68 (18–97)
<0.001
Time (days) from admission to candidemia
17 (0–151)
20.5 (0–188)
0.10
Period 2 (2008–2012)
98 (51.6)
152 (33.8)
<0.001
Private hospital
111 (58.4)
79 (41.6)
0.006
APACHE II score b
19 (3–37)
27 (0–46)
<0.001
Cancer
31 (16.3)
140 (31.1)
<0.001
  Hematologic
7 (3.7)
21 (4.7)
0.58
  Solid tumor
24 (12.6)
119 (26.4)
<0.001
Cardiac disease
62 (32.6)
161 (35.8)
0.44
Lung disease
42 (22.1)
141 (31.3)
0.02
Diabetes
49 (25.8)
107 (23.8)
0.59
Renal failure
61 (32.1)
199 (44.2)
0.004
Chronic renal failure
20 (10.5)
60 (13.3)
0.33
Dialysis
32 (16.8)
149 (33.1)
<0.001
Liver disease
13 (8.9)
56 (12.4)
0.20
Auto-immune disease
4 (2.1)
24 (5.3)
0.07
Neurologic disease
53 (27.9)
104 (23.1)
0.20
Transplant
0
3 (0.7)
0.56
Surgery
108 (56.8)
226 (50.2)
0.13
Abdominal surgery
54 (28.4)
139 (30.9)
0.53
Mechanical ventilation
117 (61.6)
378 (79.6)
<0.001
Total parenteral nutrition
42 (22.1)
97 (21.6)
0.88
Central venous catheter
176 (92.6)
422 (93.8)
0.59
Neutropenia
2 (1.1)
14 (3.1)
0.17
Prior drug/treatment exposure
  Antibiotics
181 (95.3)
436 (96.9)
0.31
  Corticosteroids
74 (38.9)
259 (57.6)
<0.001
  Other immunosuppressive drugs
9 (4.7)
29 (6.4)
0.40
  Chemotherapy
6 (3.2)
16 (3.6)
0.80
  Fluconazole prior to candidemia
36 (18.9)
65 (14.4)
0.15
Candida spp.
   C. albicans
73 (38.4)
210 (46.7)
0.055
   C. parapsilosis
43 (22.6)
67 (14.9)
0.02
   C. tropicalis
39 (20.5)
99 (22.0)
0.68
   C. glabrata
23 (12.1)
40 (8.9)
0.21
   C. krusei
5 (2.6)
11 (2.4)
1.00
   C. guilliermondii
2 (1.1)
10 (2.2)
0.52
Treatment received
176 (92.6)
301 (66.9)
<0.001
  Fluconazole
106/176 (60.2)
185/301 (61.5)
0.79
  Deoxycholate AMB
27/176 (15.3)
78/301 (25.9)
0.007
  Lipid AMB
8/176 (4.5)
13/301 (4.3)
0.91
  Echinocandin
31/176 (17.6)
21/301 (7.0)
<0.001
Time (days) from candidemia to treatment
2 (0–11)
2 (0–18)
0.12
Data are presented as a number with the percentage given in parenthesis, or as the median with the range given in parenthesis, unless specified otherwise
aStatus on day 30 was not known in 7 patients
bData available for 258 patients only
By multivariate analysis (Table  5), older age [odds ratio (OR) 1.03, 95 % confidence interval (CI) 1.01–1.05], period 1 (OR 2.49, 95 % CI 1.22–5.08), corticosteroid treatment (OR 4.00, 95 % CI 1.98–8.13) and higher APACHE II score (OR 1.05, 95 % CI 1.01–1.09) were associated with an increased risk of death. By contrast, treatment with an echinocandin (OR 0.20, 95 % CI 0.07–0.58) was associated with a higher probability of survival. Prognostic factors were also evaluated in the 745 patients who were not in an ICU (Electronic Supplementary Material Table A). Among these patients, the variables associated with 30-day mortality were period 1(OR 2.67, 95 % CI 1.33–5.33, p = 0.005), mechanical ventilation (OR 3.87, 95 % CI 1.46–10.31, p = 0.007) and antibiotic treatment (OR 5.87, 95 % CI 1.71–18.18, p = 0.004).
Table 5
Factors associated with 30-day mortality a among 640 ICU patients with candidemia by multivariate analysis
Variable
Odds ratio
95 % Confidence interval
p value
Receipt of corticosteroids
4.00
1.98–8.13
<0.001
Period 1
2.49
1.22–5.08
0.01
APACHE II score b
1.05
1.01–1.09
0.03
Age
1.03
1.01–1.05
0.003
Treatment with an echinocandin
0.20
0.07–0.58
0.003
aThe factors associated with 30-day mortality were: age [odds ratio (OR) 1.02, 95 % confidence interval (CI) 1.01–1.03, p < 0.001), period 1 (OR 2.07, 95 % CI 1.36–1.16, p = 0.001), public hospital (OR 1.68, 95 % CI 1.09–2.58, p = 0.02), solid tumor (OR 2.45, 95 % CI 1.39–4.31, p = 0.002), receipt of dialysis (2.07, 95 % CI 1.28–3.33, p = 0.003), mechanical ventilation (OR 1.60, 95 % CI 1.01–2.55, p = 0.04), corticosteroids (OR 2.31, 95 % CI 1.52–3.52, p < 0.001), while treatment with an echinocandin was protective (OR 0.45, 95 % CI 0.22–0.89, p = 0.02)
bSince the APACHE II score was available in only approximately 40 % of patients, we ran the multivariate analysis without this variable

Discussion

In this study we observed that while the 30-day crude mortality rate of patients with candidemia admitted to an ICU was very high, it decreased from 76.4 % in period 1 (2003–2007) to 60.8 % in period 2 (2008–2012). We also observed that among the predictors of outcome identified by multivariate analysis, the use of an echinocandin as primary therapy for candidemia was associated with a better outcome and that echinocandins were increasingly being used as primary therapy for candidemia in period 2.
Critically ill patients still represent a large proportion of patients who develop candidemia in tertiary care hospitals. In the present study, the proportion of candidemic patients in an ICU was 46.5 % over the entire study period and increased in period 2. As expected, compared to non-ICU patients, patients already admitted to an ICU when candidemia was diagnosed were more likely to have received antibiotics and invasive medical procedures, while cancer and transplantation were more frequent in non-ICU patients.
An interesting finding of our study relates to changes in the epidemiology and clinical management of candidemia over the 9-year period covered by this study. In parallel with the observed increase in the proportion of candidemic patients who had been exposed to fluconazole prior to being diagnosed with candidemia, we found a substantial rise in the proportion of candidemia due to C. glabrata. The association between previous exposure to fluconazole and candidemia due to C. glabrata has been extensively reported [ 1619]. While epidemiologic studies of candidemia in Latin America still show a relatively low proportion of candidemia caused by species that exhibit a lower susceptibility to fluconazole [ 14], the emergence of C. glabrata has been documented in other studies from the region [ 2022].
A dramatic finding in our study was the unacceptably high 30-day crude mortality of candidemic ICU patients, both in public and private hospitals. Indeed, two large studies published in the USA reported a decrease in the mortality rate of patients with candidemia during the last 10 years [ 5, 18]. The crude mortality rate in the EPIC study evaluating candidemia in ICUs was 42 % [ 23], and two European studies reported 30-day mortality of 47 % [ 24, 25]. The high mortality rate observed in our series may be multifactorial and include poor general clinical conditions of sick patients (especially from public hospitals), delays in making a diagnosis and the choice of treatment.
Interestingly, we observed a significant decrease in the crude mortality rate of patients with candidemia in the second period of the analysis. When we compared the clinical characteristics of patients from both periods, we found that age distribution and underlying conditions were similar, with the exception of neurologic and liver diseases, which were more common in period 2. In addition, the APACHE II score was slightly lower in period 2, although the difference was not statistically significant. We do not believe that these differences explain the significant reduction in the death rate in period 2—rather, important differences in the clinical management of candidemia did occur in period 2. Patients from the latter period were more likely to have been treated with echinocandins and less likely to have received deoxycholate amphotericin B. Various studies, including a randomized clinical trial [ 26] and a patient-level pooled analysis of randomized clinical trials [ 27], have shown that the outcome of candidemia is better when an echinocandin is used as primary therapy. Therefore, it is reasonable to assume that the observed decrease in 30-day crude mortality in period 2 may have been, at least in part, due to the increase in the use of echinocandins as primary therapy, especially since treatment with an echinocandin was an independent predictor of better outcome by the multivariate analysis.
As already reported in other studies, older age, treatment with corticosteroids and higher APACHE II score were associated with an increased risk of death [ 2, 25, 2831]. In addition, period 1 was also associated with a higher risk of death. It is possible that differences in factors related to patient care not captured in the present study contributed to the better survival observed in period 2.
Our study has a number of limitations related to its retrospective nature. For example, we did not have data to calculate incidence rates of candidemia in and outside the ICU. Likewise, data on trends in susceptibility of Candida bloodstream isolates could not be provided because of changing standards in reading the test over time. Nevertheless, according to the standards in each period, fluconazole resistance occurred in <10 % of isolates and was almost exclusively limited to C. glabrata and C. krusei (data not shown). Another limitation of our study is that the APACHE II score was not available in a significant proportion of cases, limiting the number of patients analyzed in the multivariate analysis. Likewise, since the time of central venous catheter removal is critical to an analysis of its impact on the outcome [ 32], we were not able to do such an analysis because the date of catheter removal was not available for the majority of patients.
In conclusion, we found a clear change in the epidemiology and clinical management of candidemia in ICU patients during the 9-year period of this study. The incorporation of echinocandins as primary therapy for candidemia in critically ill patients seems to be associated with better outcomes.

Acknowledgments

The authors express their sincere gratitude to all investigators who collected data for the original studies. The original studies were partially sponsored by MSD, Pfizer and United Medical.

Conflicts of interest

None.

Ethical standard

Our study was approved by the respective ethics committees of the participating hospitals and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The ethics committees granted waiver for informed consent due to the observational nature of the study.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med AINS

Kombi-Abonnement

Mit e.Med AINS erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes AINS, den Premium-Inhalten der AINS-Fachzeitschriften, inklusive einer gedruckten AINS-Zeitschrift Ihrer Wahl.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 10/2014

Intensive Care Medicine 10/2014 Zur Ausgabe

What’s New in Intensive Care

What’s new in acute liver failure?

Neu im Fachgebiet AINS

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update AINS und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise